HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Dietary Supplements Regulation FDA

NDI Notifications Take Center Stage In FDA's Evaluation Of DSHEA

  • News

Executive Summary

FDA's notice for a May 16 public meeting say it intends to ensure its "regulatory framework is flexible enough to adequately evaluate product safety without unnecessarily restricting innovation." But FDA makes clear adherence with its NDI notification requirement is focus of the spurring improvement in VMS product industry's overall compliance with regulatory framework established by DSHEA.

Table

View full table

Advertisement

Related Content

HBW Insight
FDA Debuts List For Rapidly Announcing Noncompliant Ingredients In Supplements
HBW Insight
DoJ Prosecutions: USPlabs Guilty, DMBA Firm Indicted From FDA Investigations
HBW Insight
Modernizing FDA's Supplement Industry Regulation Mapped Out In Five-Point Plan
HBW Insight
FDA Could Stick With Current Advice On NDI Notifications, Old Ingredient Evidence
HBW Insight
Supplement GMP Inspections Slowing As FDA Makes 'Potential' Data Useful
HBW Insight
DMAA, Other Stimulants Cast Shadow Over FDA Supplement Regulation – Study

Topics

Advertisement
Tags:
Dietary Supplements Regulation FDA
UsernamePublicRestriction

Register

RS148710

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By